{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Apoptosis", "Cell cycle", "Glutamate toxicity", "Reactive oxygen species", "Urolithin B"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38402341", "DateCompleted": {"Year": "2024", "Month": "02", "Day": "26"}, "DateRevised": {"Year": "2024", "Month": "02", "Day": "26"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1007/s11033-024-09236-8"], "ArticleDate": [{"Year": "2024", "Month": "02", "Day": "25"}], "Journal": {"ISSN": "1573-4978", "JournalIssue": {"Volume": "51", "Issue": "1", "PubDate": {"Year": "2024", "Month": "Feb", "Day": "25"}}, "Title": "Molecular biology reports", "ISOAbbreviation": "Mol Biol Rep"}, "ArticleTitle": "Urolithin B protects PC12 cells against glutamate-induced toxicity.", "Pagination": {"StartPage": "360", "MedlinePgn": "360"}, "Abstract": {"AbstractText": ["The involvement of malfunctioning glutamate systems in various central nervous system (CNS) disorders is widely acknowledged. Urolithin B, known for its neuroprotective and antioxidant properties, has shown potential as a therapeutic agent for these disorders. However, little is known about its protective effects against glutamate-induced toxicity in PC12 cells. Therefore, in this study, for the first time we aimed to investigate the ability of Urolithin B to reduce the cytotoxic effects of glutamate on PC12 cells.", "Different non-toxic concentrations of urolithin B were applied to PC12 cells for 24\u00a0h before exposure to glutamate (10\u00a0mM). The cells were then analyzed for cell viability, intracellular reactive oxygen species (ROS), cell cycle arrest, apoptosis, and the expression of Bax and Bcl-2 genes.", "The results of MTT assay showed that glutamate at a concentration of 10\u00a0mM and urolithin B at a concentration of 114\u00a0\u03bcM can reduce PC12 cell viability by 50%. However, urolithin B at non-toxic concentrations of 4 and 8\u00a0\u03bcM significantly reduced glutamate-induced cytotoxicity (p\u2009<\u20090.01). Interestingly, treatment with glutamate significantly enhanced the intracellular ROS levels and apoptosis rate in PC12 cells, while pre-treatment with non-toxic concentrations of urolithin B significantly reduced these cytotoxic effects. The results also showed that pre-treatment with urolithin B can decrease the Bax (p\u2009<\u20090.05) and increase the Bcl-2 (p\u2009<\u20090.01) gene expression, which was dysregulated by glutamate.", "Taken together, urolithin B may play a protective role through reducing oxidative stress and apoptosis against glutamate-induced toxicity in PC12 cells, which merits further investigations."], "CopyrightInformation": "\u00a9 2024. The Author(s), under exclusive licence to Springer Nature B.V."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Aljabouri", "ForeName": "Israa", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Rostami", "ForeName": "Mehdi", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran."}], "LastName": "Mirzavi", "ForeName": "Farshad", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Kakhki", "ForeName": "Mahla Kazemian", "Initials": "MK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Alalikhan", "ForeName": "Abbas", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Gheybi", "ForeName": "Elaheh", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Hakimi", "ForeName": "Ali", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. soukhtanloom@mums.ac.ir."}, {"Identifier": [], "Affiliation": "Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran. soukhtanloom@mums.ac.ir."}], "LastName": "Soukhtanloo", "ForeName": "Mohammad", "Initials": "M"}], "GrantList": [{"GrantID": "4011832", "Agency": "Mashhad University of Medical Sciences", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Mol Biol Rep", "NlmUniqueID": "0403234", "ISSNLinking": "0301-4851"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Reactive Oxygen Species"}, {"RegistryNumber": "3KX376GY7L", "NameOfSubstance": "Glutamic Acid"}, {"RegistryNumber": "0", "NameOfSubstance": "urolithin B"}, {"RegistryNumber": "0", "NameOfSubstance": "bcl-2-Associated X Protein"}, {"RegistryNumber": "0", "NameOfSubstance": "Neuroprotective Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Coumarins"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["metabolism"], "DescriptorName": "Reactive Oxygen Species"}, {"QualifierName": [], "DescriptorName": "PC12 Cells"}, {"QualifierName": ["toxicity", "metabolism"], "DescriptorName": "Glutamic Acid"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "bcl-2-Associated X Protein"}, {"QualifierName": [], "DescriptorName": "Oxidative Stress"}, {"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Cell Survival"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Neuroprotective Agents"}, {"QualifierName": [], "DescriptorName": "Coumarins"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Coffey CE et al (1998) Sex differences in brain aging: a quantitative magnetic resonance imaging study. Arch Neurol 55(2):169\u2013179", "ArticleIdList": ["10.1001/archneur.55.2.169", "9482358"]}, {"Citation": "Jin R et al (2002) Mechanism of activation and selectivity in a ligand-gated ion channel: structural and functional studies of GluR2 and quisqualate. Biochemistry 41(52):15635\u201315643", "ArticleIdList": ["10.1021/bi020583k", "12501192"]}, {"Citation": "Molnar E, Isaac JT (2002) Developmental and activity dependent regulation of ionotropic glutamate receptors at synapses. ScientificWorldJournal 2:27\u201347", "ArticleIdList": ["10.1100/tsw.2002.74", "12806037", "6009336"]}, {"Citation": "van Os S et al (2006) Excitatory amino acid release and electrocortical brain activity after hypoxemia in near-term lambs. Brain Dev 28(6):380\u2013388", "ArticleIdList": ["10.1016/j.braindev.2005.12.002", "16504443"]}, {"Citation": "Camins A, Pallas M, Silvestre JS (2008) Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches. Methods Find Exp Clin Pharmacol 30(1):43\u201365", "ArticleIdList": ["10.1358/mf.2008.30.1.1090962", "18389097"]}, {"Citation": "Benveniste H (2009) Glutamate, microdialysis, and cerebral ischemia: lost in translation? Anesthesiology 110(2):422\u2013425", "ArticleIdList": ["10.1097/ALN.0b013e318194b620", "19194168"]}, {"Citation": "Monaghan DT, Bridges RJ, Cotman CW (1989) The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29:365\u2013402", "ArticleIdList": ["10.1146/annurev.pa.29.040189.002053", "2543272"]}, {"Citation": "Bleich S et al (2003) Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 18(Suppl 1):S33-40", "ArticleIdList": ["10.1002/gps.933", "12973748"]}, {"Citation": "Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1(8):623\u2013634", "ArticleIdList": ["10.1016/0896-6273(88)90162-6", "2908446"]}, {"Citation": "Murphy TH et al (1989) Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 2(6):1547\u20131558", "ArticleIdList": ["10.1016/0896-6273(89)90043-3", "2576375"]}, {"Citation": "Zab\u0142ocka A, Janusz M (2008) The two faces of reactive oxygen species. Postepy Hig Med Dosw (Online) 62:118\u2013124", "ArticleIdList": ["18388851"]}, {"Citation": "Tan S, Schubert D, Maher P (2001) Oxytosis: a novel form of programmed cell death. Curr Top Med Chem 1(6):497\u2013506", "ArticleIdList": ["10.2174/1568026013394741", "11895126"]}, {"Citation": "Cerd\u00e1 B et al (2003) Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr 42(1):18\u201328", "ArticleIdList": ["10.1007/s00394-003-0396-4", "12594538"]}, {"Citation": "Garc\u00eda-Villalba R et al (2019) Identification of novel urolithin metabolites in human feces and urine after the intake of a pomegranate extract. J Agric Food Chem 67(40):11099\u201311107", "ArticleIdList": ["10.1021/acs.jafc.9b04435", "31496244"]}, {"Citation": "Esp\u00edn JC et al (2013) Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: the evidence so far. Evid Based Complement Alternat Med 2013:270418", "ArticleIdList": ["10.1155/2013/270418", "23781257", "3679724"]}, {"Citation": "Seeram NP et al (2006) Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 136(10):2481\u20132485", "ArticleIdList": ["10.1093/jn/136.10.2481", "16988113"]}, {"Citation": "Olennikov DN, Kashchenko NI, Chirikova NK (2015) In vitro bioaccessibility, human gut microbiota metabolites and hepatoprotective potential of chebulic ellagitannins: a case of Padma Hepaten<sup>\u00ae</sup> formulation. Nutrients 7(10):8456\u20138477", "ArticleIdList": ["10.3390/nu7105406", "26473917", "4632426"]}, {"Citation": "Abbasinezhad-Moud F et al (2023) The effects of urolithin B and auraptene on quinolinic acid-induced toxicity in the SH-SY5Y neuroblastoma cell line. Altern Lab Anim 51(1):30\u201338", "ArticleIdList": ["10.1177/02611929221146752", "36550678"]}, {"Citation": "Wiatrak B et al (2020) PC12 cell line: cell types, coating of culture vessels, differentiation and other culture conditions. Cells 9(4):958", "ArticleIdList": ["10.3390/cells9040958", "32295099", "7227003"]}, {"Citation": "Xie D et al (2022) The cellular model for Alzheimer\u2019s disease research: PC12 cells. Front Mol Neurosci 15:1016559", "ArticleIdList": ["10.3389/fnmol.2022.1016559", "36683856"]}, {"Citation": "Kinarivala N et al (2017) Passage variation of PC12 cells results in inconsistent susceptibility to externally induced apoptosis. ACS Chem Neurosci 8(1):82\u201388", "ArticleIdList": ["10.1021/acschemneuro.6b00208", "27718545"]}, {"Citation": "Aranda A et al (2013) Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay: a quantitative method for oxidative stress assessment of nanoparticle-treated cells. Toxicol In Vitro 27(2):954\u2013963", "ArticleIdList": ["10.1016/j.tiv.2013.01.016", "23357416"]}, {"Citation": "Ebrahimi S et al (2023) The in vitro anti-cancer synergy of neurokinin-1 receptor antagonist, aprepitant, and 5-aminolevulinic acid in glioblastoma. BioFactors 49(4):900\u2013911", "ArticleIdList": ["10.1002/biof.1953", "37092793"]}, {"Citation": "Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method. Methods 25(4):402\u2013408", "ArticleIdList": ["10.1006/meth.2001.1262", "11846609"]}, {"Citation": "Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27(1):27\u201342", "ArticleIdList": ["10.1111/ene.14108", "31631455"]}, {"Citation": "Tysnes OB, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm (Vienna) 124(8):901\u2013905", "ArticleIdList": ["10.1007/s00702-017-1686-y", "28150045"]}, {"Citation": "Chen P et al (2022) Recent advances and perspectives on the health benefits of urolithin B, a bioactive natural product derived from ellagitannins. Front Pharmacol 13:917266", "ArticleIdList": ["10.3389/fphar.2022.917266", "35814202", "9257173"]}, {"Citation": "Djedjibegovic J et al (2020) Ellagic acid-derived urolithins as modulators of oxidative stress. Oxid Med Cell Longev 2020:5194508", "ArticleIdList": ["10.1155/2020/5194508", "32774676", "7407063"]}, {"Citation": "Moujalled D, Strasser A, Liddell JR (2021) Molecular mechanisms of cell death in neurological diseases. Cell Death Differ 28(7):2029\u20132044", "ArticleIdList": ["10.1038/s41418-021-00814-y", "34099897", "8257776"]}, {"Citation": "Venderova K, Park DS (2012) Programmed cell death in Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2(8):a009365", "ArticleIdList": ["10.1101/cshperspect.a009365", "22908196", "3405826"]}, {"Citation": "Eidizade F et al (2023) Inhibition of glioblastoma proliferation, invasion, and migration by urolithin B through inducing G0/G1 arrest and targeting MMP-2/-9 expression and activity. BioFactors 49(2):379\u2013389", "ArticleIdList": ["10.1002/biof.1915", "36310375"]}, {"Citation": "Rahimi-Kalateh Shah Mohammad G et al (2023) Urolithin B loaded in cerium oxide nanoparticles enhances the anti-glioblastoma effects of free urolithin B in vitro. J Trace Elem Med Biol 78:127186", "ArticleIdList": ["10.1016/j.jtemb.2023.127186", "37148696"]}, {"Citation": "Lv MY et al (2019) Urolithin B suppresses tumor growth in hepatocellular carcinoma through inducing the inactivation of Wnt/\u03b2-catenin signaling. J Cell Biochem 120(10):17273\u201317282", "ArticleIdList": ["10.1002/jcb.28989", "31218741"]}, {"Citation": "S\u00e1nchez-Gonz\u00e1lez C et al (2014) Walnut polyphenol metabolites, urolithins A and B, inhibit the expression of the prostate-specific antigen and the androgen receptor in prostate cancer cells. Food Funct 5(11):2922\u20132930", "ArticleIdList": ["10.1039/C4FO00542B", "25214070"]}, {"Citation": "Perc\u00e1rio S et al (2020) Oxidative stress in Parkinson\u2019s disease: potential benefits of antioxidant supplementation. Oxid Med Cell Longev 2020:2360872", "ArticleIdList": ["10.1155/2020/2360872", "33101584", "7576349"]}, {"Citation": "DaSilva NA et al (2019) Pomegranate ellagitannin-gut microbial-derived metabolites, urolithins, inhibit neuroinflammation in vitro. Nutr Neurosci 22(3):185\u2013195", "ArticleIdList": ["10.1080/1028415X.2017.1360558", "28784051"]}, {"Citation": "Lee G et al (2019) Anti-inflammatory and antioxidant mechanisms of urolithin B in activated microglia. Phytomedicine 55:50\u201357", "ArticleIdList": ["10.1016/j.phymed.2018.06.032", "30668443"]}, {"Citation": "Qiu Z et al (2013) In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem Toxicol 59:428\u2013437", "ArticleIdList": ["10.1016/j.fct.2013.06.025", "23811531"]}]}], "History": [{"Year": "2023", "Month": "11", "Day": "11"}, {"Year": "2024", "Month": "1", "Day": "9"}, {"Year": "2024", "Month": "2", "Day": "26", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "2", "Day": "25", "Hour": "0", "Minute": "42"}, {"Year": "2024", "Month": "2", "Day": "24", "Hour": "23", "Minute": "27"}], "PublicationStatus": "epublish", "ArticleIdList": ["38402341", "10.1007/s11033-024-09236-8", "10.1007/s11033-024-09236-8"]}}]}